furoscix

[anonymous]

LOL! It’s not always greener on the other side. A lot of companies are shady. The pay is decent by the way, but you’re right about the car allowance. My poor car has been taking a beating and what they are paying is not enough… For the car that is.

You are right about SB. I heard somebody in Florida sued her and 1 and her entire team testified against her but they all pretty much left and she’s still there. my manager is OK, but he thinks that she is crazy as well. She’s kind of creepy looking.

It’s not a bad job. I think it’s better than big Pharma. I think if they remove a few of the bad seeds, things would improve big time

Please tell me the basis of the lawsuit against SB! I interviewed with her and I got the heebee jeebees from her. I decided not to pursue it.

 

[anonymous]

Seems like a sinking ship... employees just milking checks until the well runs dry or they get another opportunity at a company with better long term prospects. Definitely hiring and only able to retain the bottom of the barrel talent.

 

[anonymous]

Is it really as bad as people are suggesting?

The product appears to be growing in popularity based on the quarterly numbers. Anyone have good experiences, or is it all bad?

 

[anonymous]

Why is the stock getting absolutely pulverized? Down >40% ytd

 

[anonymous]

Why is the stock getting absolutely pulverized? Down >40% ytd

My guess is that the market is not expecting strong growth, and that the quarterly results most recently mixed expectations - largely in part due to a one time financing expense, I believe, as well as due to a somewhat small revenue miss, potentially attributable to the coverage gap rebates as discussed on the Q3 conference call.

Management seems to feel that Q4 was going better at the time of the call, and expects more tailwinds in Q1 2025 onwards with the potentially favorable updates to Schedule D, amongst other things. Just my 2 cents. Please verify all of this, and do not take it as authoritative in any way. Always do your own due diligence. This is not financial advice.

 

[anonymous]

Could it be everyone has figured out you can do the same thing by just giving them a higher dose of bumex for cents on the dollar?

My guess is that the market is not expecting strong growth, and that the quarterly results most recently mixed expectations - largely in part due to a one time financing expense, I believe, as well as due to a somewhat small revenue miss, potentially attributable to the coverage gap rebates as discussed on the Q3 conference call.

Management seems to feel that Q4 was going better at the time of the call, and expects more tailwinds in Q1 2025 onwards with the potentially favorable updates to Schedule D, amongst other things. Just my 2 cents. Please verify all of this, and do not take it as authoritative in any way. Always do your own due diligence. This is not financial advice.

 

[anonymous]

Could it be everyone has figured out you can do the same thing by just giving them a higher dose of bumex for cents on the dollar?

If that were always true, this option would not be seeing sequential growth and expanded use, in my opinion.

 

[anonymous]

If that were always true, this option would not be seeing sequential growth and expanded use, in my opinion.

Additionally, while bumex may offer twice as much bioavailability as furosemide, I believe the odds significantly favor furosemide when used subcutaneously via furoscix.